RT Journal Article
SR Electronic
T1 Evolution of COVID-19 cases in selected low- and middle-income countries: past the herd immunity peak?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.26.20201814
DO 10.1101/2020.09.26.20201814
A1 Lexmond, Axel S.
A1 Nouwen, Carlijn J.A.
A1 Fourtassi, Othmane
A1 Callan, J. Paul
YR 2020
UL http://medrxiv.org/content/early/2020/10/01/2020.09.26.20201814.1.abstract
AB COVID-19 cases have peaked and declined rapidly in many low- and middle-income countries in recent months, in some cases after control measures were relaxed. For 11 such countries, the hypothesis that these countries have reached herd immunity warrants serious consideration. The Reed-Frost model, perhaps the simplest description for the evolution of cases in an epidemic, with only a few constant parameters, fits the observed case data remarkably well, and yields parameter values that are reasonable. The model results give infection rates of 45% and 79%, above the herd immunity thresholds for each country (under current social distancing conditions). Reproduction numbers range between 1.4 and 2.0, indicating that epidemic curves were “flattened” but not “suppressed”. Between 0.05% and 2.86% of cases have been detected according to the estimates – values which are consistent with findings from serological and T-cell immunity studies. Overall infection fatality ratios for two of three countries studied are lower than expected from reported infection fatality ratios by age (which are based on studies of several high-income countries). COVID-19 may have lower age-specific fatality risks in some countries, due to differences in immune-response, prior exposure to coronaviruses, disease characteristics or other factors. We find that the herd immunity hypothesis would not have fit the evolution of reported cases in several European countries, even just after the initial peaks – and subsequent resurgences of cases obviously prove that those countries have infection rates well below herd immunity levels. Our hypothesis that the 11 countries we studied have reached herd immunity should now be tested further, through serological and T-cell-immunity studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received to support this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We used only publicly available, anonymised data and applied only statistical analysis on this data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used is publicly available data (as published by WHO). Relevant sources are included in footnotes where applicable. All equations and methods used in this article are described in the supplementary material which we submit at the same time as a separate publication. https://covid19.who.int/?gclid=Cj0KCQjwqrb7BRDlARIsACwGad70vhvBpGrU5OzlW0YlQIWvqdC5JdvmP6jSYm14cVkMyRsMnQvtILIaAhwcEALw_wcB